Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 16, 2021 08:00 ET | Source: Ayala Pharmaceuticals

Ayala Pharmaceuticals Presents Preliminary Clinical Data from the Ongoing Phase 2 ACCURACY Trial and Announces Pre-Clinical Proof of Concept Data for Enhanced Activity of AL101 in Combination with Approved Cancer Therapies in ACC

- Posters presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2021 - Preliminary data showed meaningful clinical activity of AL101 6mg monotherapy with 70% disease...
September 02, 2021 08:00 ET | Source: Ayala Pharmaceuticals

Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

REHOVOT, Israel and WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small...
September 01, 2021 08:00 ET | Source: Ayala Pharmaceuticals

Ayala Pharmaceuticals to Present Clinical Data from Ongoing Phase 2 ACCURACY Trial and New Preclinical Results from Combination Study of AL101 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021

REHOVOT, Israel and WILMINGTON, Del., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small...
August 13, 2021 08:00 ET | Source: Ayala Pharmaceuticals

Ayala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

- Enrolled the First Patient in the Phase 2/3 Pivotal Trial of AL102 for the Treatment of Desmoid Tumors - Multiple Near-Term Milestones Across Clinical-Stage Pipeline - Updated ACCURACY Trial...
July 06, 2021 09:00 ET | Source: Ayala Pharmaceuticals

Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference

REHOVOT, Israel & WILMINGTON, Del., July 06, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing...
May 27, 2021 09:01 ET | Source: Ayala Pharmaceuticals

Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

REHOVOT, Israel and WILMINGTON, Del., May 27, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small...
May 14, 2021 08:15 ET | Source: Ayala Pharmaceuticals

Ayala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

- First Patient Dosed in Phase 1 AL102 Combination Trial with Novartis’ Anti-BCMA Agent for the Treatment of Multiple Myeloma - - On Track to Initiate AL102 Phase 2/3 Pivotal Trial for the...
April 21, 2021 08:00 ET | Source: Ayala Pharmaceuticals

Ayala Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of AL102 in Combination with BCMA Targeting Agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma

REHOVOT, Israel and WILMINGTON, Del., April 21, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small...
March 25, 2021 08:00 ET | Source: Ayala Pharmaceuticals

Ayala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business Update

- Completed $25 Million Strategic Financing; Extending Cash Runway into 2023 - Accelerated Development of AL102 Desmoid Tumor Program into Phase 2/3 Pivotal Trial - On...
March 02, 2021 08:00 ET | Source: Ayala Pharmaceuticals

Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

REHOVOT, Israel and WILMINGTON, Del., March 02, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small...